Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Pituitary Adenoma, Pituitary Neuroendocrine Tumor

In brief

The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will: * Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks * Visit the clinic three months after surgery for checkups and tests * Keep a diary of their symptoms

Key facts

Study ID
NCT06679816
Run by
Beijing Tiantan Hospital
People needed
882
Starts
2024-12-04
Expected to finish
2026-06-30
Last updated by the study team
2025-01-14

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.